Recent developments The Turkish Medicines and Medical Devices Agency (the “TİTCK”) recently announced new procedures for the medicine licensing process depending on the payment status of the scientific analysis and assessment fees. Background Scientific analysis and assessment fees are among the mandatory fees in the medicine licensing process. In early January, the TİTCK announced an update to scientific analysis and assessment fees – including price tariffs – and stated that the deadline for the payment of scientific analysis and assessment fees was February 17, 2017. Companies that missed the payment deadline have had their license application waitlisted until November 30, 2017. Companies that do not pay their scientific analysis and assessment fees by November 30 will have their applications cancelled. For more information on scientific analysis and assessment fees, please refer to our previous legal alert of January 11, 2017. What the Announcement Says The TİTCK recently announced the following procedures on its website.
– If the laboratory analysis on the relevant products was initiated, the analysis will be completed; if the laboratory analysis has not yet been initiated, the analysis process will be suspended. – Upon the payment of the scientific analysis and assessment fees, the licensing process will resume as of the date notified by the TİTCK. – Priority or high priority applications will be fast-tracked for the active licensing process (the “Active Process List”) upon the payment of the scientific analysis and assessment fees. – The products listed on the Process Waiting List will be transferred to the Active Process List in accordance with the number of licensed products that were on the Active Process List and the licensing schedule. Applications transferred to the Active Process List will be announced within the first five working days of each month until November 30, 2017.
– Priority or high priority applications will be placed immediately on the Active Process List. – Other applications will be placed on the Active Process List only upon the payment of the scientific analysis and assessment fees.
– Priority or high priority applications will be placed on the Active Process List upon the payment of the scientific analysis and assessment fees. – The TİTCK will notify the applicant of the active process commencement date and the deadline for the payment of the scientific analysis and assessment fees. Such applications will be waitlisted until the commencement of the active process. The final waitlist and licensing process for 2018 will be announced in the December 2017 evaluation. Conclusion The TİTCK continues to provide pharmaceutical companies detailed guidelines on the medicine licensing process. Pharmaceutical companies should take note of the new procedural steps for their license applications and should follow future announcements made by the TİTCK. |
For further information,
please contact:
Legal Alerts
28/03/2017 09/06/2022
TİTCK Announces New Procedures for License Applications
Legal Alerts
Healthcare
General
Recommended for you
- Doing Business in Türkiye 2024
- Changes to Mandatory Reserves
- TCMB Zorunlu Karşılıklarında Yeni İstisna
- Proposed Amendment to the Legislation on Dispute Resolution Concerning Internet Domain Names
- Recent Developments in the Healthcare Sector – 20 August 2021
- Healthcare & Life Sciences Newsletter
- How will the Social Security Institution now notify employers?
- UNCITRAL 2021 Expedited Arbitration Rules Entered Into Force
- Turkey Signs Singapore Convention on Cross-Border Mediations
- IPO Conditions Tightened
- New Market Structure of Borsa Istanbul – November 2019